ANNUAL GENERAL MEETING OF XVIVO PERFUSION AB (PUBL)
The Annual General Meeting of XVIVO Perfusion AB (publ) will take place on Tuesday April 29, 2014, at 5 p.m. in the company's premises at Mässans gata 10 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Wednesday, April 23, 2014.
Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Gothenburg, Sweden, Att: Catrin Olsson, by phone +46 31-788 21 53, by fax +46 31-788 21 69 or by e-mail firstname.lastname@example.org. Name/business name, personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.xvivoperfusion.com.
Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting. Such registration must be carried out no later than Wednesday, April 23, 2014.
Attachment: Full notice (in Swedish)
March 28, 2014
XVIVO Perfusion AB (publ)
Queries should be addressed to:
Fredrik Mattsson, Chairman of the Board, phone +46 8-614 00 20
Christoffer Rosenblad, CFO, phone +46 31-788 21 59
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 28, 2014 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se .
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com